

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



August 3, 2026

Company name: Mochida Pharmaceutical Co., Ltd.
Name of representative: Naoyuki Mochida, Representative
Director, President
(Securities code: 4534 Prime Market, TSE)
Inquiries: Kenichi Miyamoto, Head of
Finance & Accounting Department
(Telephone: +81-3-3358-7211)

Notice Regarding the Status of Acquisition of Own Shares
(Share Repurchase under the provisions of the Articles of Incorporation pursuant to Article 165,
Paragraph 2 of the Companies Act)

Mochida Pharmaceutical Co., Ltd. (the “Company”) hereby announces the status of the acquisition of its own shares in accordance with Article 156 of the Companies Act, as applied pursuant to Article 165, Paragraph 3 of the same Act, as described below.

(1) Class of shares acquired	Common shares of the Company
(2) Total number of shares acquired	90,600 shares
(3) Total amount of share acquisition costs	286,404,500 yen
(4) Period of acquisition	From July 1, 2026 to July 31, 2026(on a trade-date basis)
(5) Method of acquisition	Market purchases on the Tokyo Stock Exchange based on a discretionary dealing contract

(Reference)

1. Details of the resolution of the Board of Directors held on March 30, 2026

(1) Class of shares to be acquired	Common shares of the Company
(2) Total number of shares to be acquired	Up to 530,000 shares (1.50% of the total number of issued shares excluding own shares)
(3) Total amount of share acquisition costs	Up to 2,000,000,000 yen
(4) Period of acquisition	From May 18, 2026 to December 18, 2026
(5) Method of acquisition	Market purchases on the Tokyo Stock Exchange based on a discretionary dealing contract Note: Depending on market conditions, all or part of the planned acquisition may not be carried out.

2. Total number of shares acquired pursuant to the above resolution (as of July 31, 2026)

(1) Total number of shares acquired	186,500 shares
(2) Total amount of share acquisition costs	603,565,000 yen